+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Immune Checkpoint Inhibitor"

From
From
From
From
From
Spotlight on Antibody-Drug Conjugates - Product Thumbnail Image

Spotlight on Antibody-Drug Conjugates

  • Report
  • September 2019
  • 71 Pages
  • Global
Keytruda (pembrolizumab; Merck & Co) Drug Overview 2019 - Product Thumbnail Image

Keytruda (pembrolizumab; Merck & Co) Drug Overview 2019

  • Drug Pipelines
  • September 2019
  • 141 Pages
  • Global
From
From
From
From
Disease Analysis: Head and Neck Cancer - Product Thumbnail Image

Disease Analysis: Head and Neck Cancer

  • Report
  • March 2021
  • 77 Pages
  • Global
Loading Indicator

Immune Checkpoint Inhibitor drugs are a type of immunotherapy used to treat immune disorders. They work by blocking proteins that act as “checkpoints” in the immune system, allowing the body to recognize and attack cancer cells. These drugs are used to treat a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. They are also used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease. Immune Checkpoint Inhibitor drugs are a relatively new form of treatment, and the market is still in its early stages. However, the potential of these drugs has led to a surge in research and development, with many companies investing in the development of new drugs. Some of the major companies in the Immune Checkpoint Inhibitor market include Bristol-Myers Squibb, Merck, AstraZeneca, Roche, and Novartis. Other companies such as Pfizer, AbbVie, and Johnson & Johnson are also involved in the development of these drugs. Show Less Read more